Biosensors Achieves Its Highest-Ever Profile at EuroPCR 2014

LEADERS FREE Patient Population Data

Following completion of enrolment, the baseline population data from Biosensors’ LEADERS FREE study was presented for the first time at EuroPCR 2014 by Dr. Philip Urban.  This study, involving BioFreedom , Biosensors’ novel polymer and carrier-free drug-coated stent (DCS), is the world's first prospective randomised double-blind study employing only a one-month course of DAPT after implantation of an active stent. The study patients, specifically selected for their high risk of bleeding, were found to be significantly older and have more co-morbidities than a typical 'all comers' patient trial population.


Watch the interview of Dr Urban

More details about BioFreedom™